Evidence map›Paper›PMID 40766423›Full record

ArticlebioRxiv : the preprint server for biology2025

CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunity.

Lauren Duhamel, Yiming J Zhang, William Pinney, Elizabeth Fink, Qingyang Henry Zhao, Anna Romanov, Jordan A Stinson, Luciano Santollani, Joseph R Palmeri, Owen T Porth and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lauren DuhamelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8859-6114
Yiming J ZhangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8102-3815
William PinneyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Elizabeth FinkKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-0380-7961
Qingyang Henry ZhaoDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anna RomanovDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-1239-4946
Jordan A StinsonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-3281-3172
Luciano SantollaniKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0009-7225-8303
Joseph R PalmeriKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-3932-9124
Owen T PorthDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0004-8145-991X
Darrell J IrvineHoward Hughes Medical Institute, Chevy Chase, MD, USA.ORCID 0000-0002-8637-1405
K Dane WittrupDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Localized immunotherapy using alum-binding therapeuticsR01EB031082 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IRVINE, DARRELL J, WITTRUP, KARL DANE · 2021 to 2024
$2.1M
NCI NIH HHS P30 CA014051NIBIB NIH HHS R01 EB031082
6 · The paper itself

Abstract

CD45 plays a central role in immune signal regulation by controlling the spatial dynamics of phosphatase activity through steric segregation of its bulky rigid extracellular domain. To modulate CD45 activity, here we develop and characterize protein engineering approaches to induce multivalent clustering of CD45, effectively mimicking the endogenous local receptor sequestration during immune synapse formation. In doing so, we engineer a biologic that enables precise, tunable control over CD45 surface localization and activity. CD45 sequestration exhibited striking synergy when administered in combination with intratumorally anchored IL-12 therapy, markedly delaying tumor progression and extending survival in syngeneic murine melanoma and carcinoma models. Immune profiling revealed that CD8

Identifiers

PMID40766423
PMCPMC12324387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.